These HIF2α inhibitors show high safety and effectiveness in both animal experiments and clinical trials, which can significantly inhibit tumor growth in patients with metastatic clear cell renal cell carcinoma (ccRCC), with proven safety and high dose tolerance (Chen et al., 2016; Cho et al., 2016). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.